Featured Research

from universities, journals, and other organizations

Signaling Pathway In Melanoma Could Provide Target For Diagnosis, Prevention And Treatment

Date:
December 6, 2002
Source:
Emory University Health Sciences Center
Summary:
Scientists at Emory University School of Medicine have identified a signaling pathway that is turned on when benign moles turn into early-stage malignant melanoma. The pathway could provide a new target for the diagnosis, prevention and treatment of the most lethal form of skin cancer. The research was reported in the December issue of the journal Clinical Cancer Research.

ATLANTA -- Scientists at Emory University School of Medicine have identified a signaling pathway that is turned on when benign moles turn into early-stage malignant melanoma. The pathway could provide a new target for the diagnosis, prevention and treatment of the most lethal form of skin cancer. The research was reported in the December issue of the journal Clinical Cancer Research.

A team of Emory scientists led by Jack L. Arbiser, MD, PhD, found that the signaling pathway called mitogen activated protein kinase (MAP kinase) is abnormally turned on in melanoma, particularly in its early stages. The investigators studied levels of activated MAP kinase in 131 tissue samples from precancerous moles (atypical nevi) and malignant melanomas. They found high levels of activated MAP kinase in early melanomas, but not in moles that are the precursors to melanoma.

In addition to MAP kinase activation, the Emory investigators studied two genes known to be up-regulated by the MAP kinase –– vascular endothelial growth factor (VEGF) and tissue factor (TF). These genes also are known to be powerful stimulators of angiogenesis, which is the growth of microscopic blood vessels that nourishes cancerous tumors and leads to unregulated cell growth. The development of dormant tumors into actively proliferating tumors requires angiogenesis.

Dr. Arbiser and his colleagues did not find evidence of VEGF and TF in precancerous moles, but they did find these two target genes present in early melanomas.

According to the American Cancer Society, patients who have melanoma that has not spread below the skin have a survival rate of 96 percent beyond five years. But as the tumor begins to grow, the survival rate falls to 61 percent if the disease has reached the lymph nodes below the skin and 12 percent if it has spread to other organs in the body. Melanoma is the sixth most common form of cancer in U.S. men and the seventh most common form in U.S. women. The Cancer Society estimates that 53,600 new cases of melanoma will be diagnosed in the U.S. in 2002 and that 7,400 people will die from it.

"Our finding is of interest for two reasons," Dr. Arbiser says. "First, it may help physicians determine whether a mole is malignant, which is often difficult. Second, drugs that target MAP kinase could become available as creams and help prevent the change of moles to melanomas. Our study identifies MAP kinase as a pathway that must be targeted in the prevention and treatment of melanoma."


Story Source:

The above story is based on materials provided by Emory University Health Sciences Center. Note: Materials may be edited for content and length.


Cite This Page:

Emory University Health Sciences Center. "Signaling Pathway In Melanoma Could Provide Target For Diagnosis, Prevention And Treatment." ScienceDaily. ScienceDaily, 6 December 2002. <www.sciencedaily.com/releases/2002/12/021206074730.htm>.
Emory University Health Sciences Center. (2002, December 6). Signaling Pathway In Melanoma Could Provide Target For Diagnosis, Prevention And Treatment. ScienceDaily. Retrieved August 21, 2014 from www.sciencedaily.com/releases/2002/12/021206074730.htm
Emory University Health Sciences Center. "Signaling Pathway In Melanoma Could Provide Target For Diagnosis, Prevention And Treatment." ScienceDaily. www.sciencedaily.com/releases/2002/12/021206074730.htm (accessed August 21, 2014).

Share This




More Health & Medicine News

Thursday, August 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
Ramen Health Risks: The Dark Side of the Noodle

Ramen Health Risks: The Dark Side of the Noodle

AP (Aug. 21, 2014) South Koreans eat more instant ramen noodles per capita than anywhere else in the world. But American researchers say eating too much may increase the risk of diabetes, heart disease and stroke. (Aug. 21) Video provided by AP
Powered by NewsLook.com
Possible Ebola Patient in Isolation at California Hospital

Possible Ebola Patient in Isolation at California Hospital

Reuters - US Online Video (Aug. 20, 2014) A patient who may have been exposed to the Ebola virus is in isolation at the Kaiser Permanente South Sacramento Medical Center. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins